Transcriptome sequencing of BCG-treated T1HG bladder cancer patients identifies an EMT-basal subgroup with immune suppressive characteristics at high risk of BCG failure
Florus C. de Jong(Erasmus MC Cancer Institute), Tahlita C.M. Zuiverloon(Erasmus MC), Sébastien Rinaldetti(Heidelberg University), James C. Costello(University of Colorado Cancer Center), Ellen C. Zwarthoff(Erasmus MC), Jolien T. M. Mensink(Erasmus MC Cancer Institute), Robert F. Hoedemaeker(PathoFinder (Netherlands)), Deric K. E. van der Schoot(Amphia Ziekenhuis), Teemu D. Laajala(University of Turku), Joost L. Boormans(Erasmus MC), Egbert R. Boevé(Hôpitaux Universitaires Henri-Mondor), Alexandra Madè, Dan Theodorescu(University of Arizona)
Cited by 0
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
|Proceedings of the National Academy of Sciences|2013|1.4k
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|798
Advances in bladder cancer biology and therapy
|Nature reviews. Cancer|2020|783
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|660